These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 21347786)

  • 1. DNA repair gene and MTHFR gene polymorphisms as prognostic markers in locally advanced adenocarcinoma of the esophagus or stomach treated with cisplatin and 5-fluorouracil-based neoadjuvant chemotherapy.
    Ott K; Rachakonda PS; Panzram B; Keller G; Lordick F; Becker K; Langer R; Buechler M; Hemminki K; Kumar R
    Ann Surg Oncol; 2011 Sep; 18(9):2688-98. PubMed ID: 21347786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The polymorphisms of TS and MTHFR predict survival of gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy in Chinese population.
    Huang ZH; Hua D; Li LH
    Cancer Chemother Pharmacol; 2009 Apr; 63(5):911-8. PubMed ID: 18704422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CyclinD1 and interleukin-1 receptor antagonist polymorphisms are associated with prognosis in neoadjuvant-treated gastric carcinoma.
    Stocker G; Ott K; Henningsen N; Becker K; Hapfelmeier A; Lordick F; Hois S; Plaschke S; Höfler H; Keller G
    Eur J Cancer; 2009 Dec; 45(18):3326-35. PubMed ID: 19822419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prediction of response to neoadjuvant chemotherapy in Barrett's carcinoma by quantitative gene expression analysis].
    Langer R; Specht K; Becker K; Ewald P; Sarbia M; Busch R; Feith M; Stein HJ; Siewert JR; Höfler H
    Verh Dtsch Ges Pathol; 2004; 88():207-13. PubMed ID: 16892554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between glutathione S-transferase P1 (GSTP1), X-ray repair cross complementing group 1 (XRCC1) and 5,10-methylenetetrahydrofolate reductase (5,10-MTHFR) gene polymorphisms and response to chemotherapy in advanced gastric cancer.
    Ji M; Xu B; Jiang JT; Wu J; Li XD; Zhao WQ; Zhang HY; Zhou WJ; Wu CP
    Onkologie; 2013; 36(6):335-40. PubMed ID: 23774147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of response and prognosis by a score including only pretherapeutic parameters in 410 neoadjuvant treated gastric cancer patients.
    Lorenzen S; Blank S; Lordick F; Siewert JR; Ott K
    Ann Surg Oncol; 2012 Jul; 19(7):2119-27. PubMed ID: 22395980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Folate intake along with genetic polymorphisms in methylenetetrahydrofolate reductase and thymidylate synthase in patients with advanced gastric cancer.
    Shitara K; Muro K; Ito S; Sawaki A; Tajika M; Kawai H; Yokota T; Takahari D; Shibata T; Ura T; Ito H; Hosono S; Kawase T; Watanabe M; Tajima K; Yatabe Y; Tanaka H; Matsuo K
    Cancer Epidemiol Biomarkers Prev; 2010 May; 19(5):1311-9. PubMed ID: 20447923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer.
    Wu X; Gu J; Wu TT; Swisher SG; Liao Z; Correa AM; Liu J; Etzel CJ; Amos CI; Huang M; Chiang SS; Milas L; Hittelman WN; Ajani JA
    J Clin Oncol; 2006 Aug; 24(23):3789-98. PubMed ID: 16785472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy.
    Quintela-Fandino M; Hitt R; Medina PP; Gamarra S; Manso L; Cortes-Funes H; Sanchez-Cespedes M
    J Clin Oncol; 2006 Sep; 24(26):4333-9. PubMed ID: 16896002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perineural invasion after preoperative chemotherapy predicts poor survival in patients with locally advanced gastric cancer: gene expression analysis with pathologic validation.
    Jhawer M; Coit D; Brennan M; Qin LX; Gonen M; Klimstra D; Tang L; Kelsen DP; Shah MA
    Am J Clin Oncol; 2009 Aug; 32(4):356-62. PubMed ID: 19381079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polymorphisms of DNA repair gene XRCC3 Thr241Met and risk of gastric cancer in a Chinese population.
    Shen H; Wang X; Hu Z; Zhang Z; Xu Y; Hu X; Guo J; Wei Q
    Cancer Lett; 2004 Mar; 206(1):51-8. PubMed ID: 15019159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer.
    Kalikaki A; Kanaki M; Vassalou H; Souglakos J; Voutsina A; Georgoulias V; Mavroudis D
    Clin Lung Cancer; 2009 Mar; 10(2):118-23. PubMed ID: 19362955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenetic analyses of a phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil and leucovorin plus either oxaliplatin or cisplatin: a study of the arbeitsgemeinschaft internistische onkologie.
    Goekkurt E; Al-Batran SE; Hartmann JT; Mogck U; Schuch G; Kramer M; Jaeger E; Bokemeyer C; Ehninger G; Stoehlmacher J
    J Clin Oncol; 2009 Jun; 27(17):2863-73. PubMed ID: 19332728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy.
    Ruzzo A; Graziano F; Kawakami K; Watanabe G; Santini D; Catalano V; Bisonni R; Canestrari E; Ficarelli R; Menichetti ET; Mari D; Testa E; Silva R; Vincenzi B; Giordani P; Cascinu S; Giustini L; Tonini G; Magnani M
    J Clin Oncol; 2006 Apr; 24(12):1883-91. PubMed ID: 16622263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy.
    Gurubhagavatula S; Liu G; Park S; Zhou W; Su L; Wain JC; Lynch TJ; Neuberg DS; Christiani DC
    J Clin Oncol; 2004 Jul; 22(13):2594-601. PubMed ID: 15173214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A haplotype of the methylenetetrahydrofolate reductase gene predicts poor tumor response in rectal cancer patients receiving preoperative chemoradiation.
    Terrazzino S; Agostini M; Pucciarelli S; Pasetto LM; Friso ML; Ambrosi A; Lisi V; Leon A; Lise M; Nitti D
    Pharmacogenet Genomics; 2006 Nov; 16(11):817-24. PubMed ID: 17047490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TP53 codon 72 polymorphism associated with prognosis in patients with advanced gastric cancer treated with paclitaxel and cisplatin.
    Kim JG; Sohn SK; Chae YS; Song HS; Kwon KY; Do YR; Kim MK; Lee KH; Hyun MS; Lee WS; Sohn CH; Jung JS; Kim GC; Chung HY; Yu W
    Cancer Chemother Pharmacol; 2009 Jul; 64(2):355-60. PubMed ID: 19052714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term results of a phase II trial of neoadjuvant chemotherapy followed by esophagectomy for locally advanced esophageal neoplasm.
    Pennathur A; Luketich JD; Landreneau RJ; Ward J; Christie NA; Gibson MK; Schuchert M; Cooper K; Land SR; Belani CP
    Ann Thorac Surg; 2008 Jun; 85(6):1930-6; discussion 1936-7. PubMed ID: 18498797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thymidylate synthase protein expression: Association with response to neoadjuvant chemotherapy and resection for locally advanced gastric and gastroesophageal adenocarcinoma.
    Alexander HR; Grem JL; Hamilton JM; Pass HI; Hong M; Fraker DL; Steinberg SM; McAtee N; Allegra BC; Johnston PG
    Cancer J Sci Am; 1995; 1(1):49-54. PubMed ID: 9166454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
    Jin J; Liao Z; Zhang Z; Ajani J; Swisher S; Chang JY; Jeter M; Guerrero T; Stevens CW; Vaporciyan A; Putnam J; Walsh G; Smythe R; Roth J; Yao J; Allen P; Cox JD; Komaki R
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):427-36. PubMed ID: 15380576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.